Navigation Links
Exubera could mean the end of an insulin injection era for diabetics

Diabetes and cancer remain the most feared diseases all around the world. Researchers have now come up with an insulin inhaler, potentially offering adult diabetics an alternative to injections// for controlling their blood sugar. The drug is yet to be approved by the FDA.

If approved, the drug, known as Exubera, would mean an end to the insulin injections taken by millions worldwide. The product works by releasing an insulin-powder cloud inhaled via a handheld plastic machine similar to the inhalers used for asthma and allergy. The drug has been in development for a decade and is now backed by a joint venture between Pfizer, Sanofi-Aventis and Nektar Therapeutics.

Pfizer presented several studies showing Exubera controlled blood sugar as well as insulin shots for up to two years in patients with both forms of diabetes. Questions remain about whether adult Type 1 diabetics can expect to achieve tight glycemic control with Exubera.

Up to two-thirds of all diabetics do not adequately control their blood sugar, according to the American Academy of Clinical Endocrinologists. Poor control over the long term can lead to blood vessel and organ damage, blindness, and kidney failure and foot ailments.

Despite approval, many would still have to use needles, because the drug is not a replacement for the currently available longer-acting insulin. In addition, patients who smoke will be excluded from taking the drug, because of evidence that damage from cigarettes boosts patients` exposure to insulin.

'To have people rush to the this product saying, `I can throw away my syringes` ... is simply an incorrect message and that needs to be emphasized more,' said Dr. Paul D. Woolf, chief of medicine at Crozer Chester Medical Center in Upland, Pa., and acting chair of the advisory panel. I think the use of insulin without a needle, the siren call of that is almost irresistible,' said Rebecca W. Killion, the panel`s patient representative -- herself a diabetic. 'The practicality issue, though ... is huge.' The companies did not seek approval for adolescents and children -- two groups that could benefit greatly from a needle-free product. It has been proposed to restart pediatric studies with special emphasis on breathing problems.
'"/>




Related medicine news :

1. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
2. Exubera is effective in diabetes patients with cold or flu
3. Virus Level could Predict Cervical Cancer Risk
4. Beware of the oral patch! It could be cancer!!!
5. Prozac miracle could end in disaster
6. Wonder drug - could end in disaster
7. Pollution could be a risk
8. Fright could be more harmful
9. Pregnant smokers could harm their child
10. Snoring could be a warning
11. Anthrax drug doxycycline could stunt fetal growth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... , ... May 06, 2016 , ... ... arrival of Sovaldi, which made headlines mostly for its cost despite its potential ... and moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have ...
(Date:5/6/2016)... ... 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, PhD, joins ... Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali Khan, MD, ... Officer at Health Care Service Corporation (Blue Cross and Blue Shield of Illinois, ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an ... that it meets its goals and delivers value to the wool industry., The RWS ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May 6 - ... on steep California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in ... will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with ...
(Date:5/5/2016)... Indianapolis, IN (PRWEB) , ... May 05, 2016 ... ... employee benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition ... & Smoak Benefits has a dedicated team of compliance, wellness, human resources, and ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology: